ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -22 مورد

Rilpivirine, emtricitabine, and tenofovir alafenamide: Drug information

Rilpivirine, emtricitabine, and tenofovir alafenamide: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
ALERT: US Boxed Warning
HIV-1 and hepatitis B coinfection:

Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and hepatitis B virus (HBV) who have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate, and may occur with discontinuation of emtricitabine/rilpivirine/tenofovir alafenamide.

Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients with HIV-1 and HBV who discontinue emtricitabine/rilpivirine/tenofovir alafenamide. If appropriate, anti-hepatitis B therapy may be warranted.

Brand Names: US
  • Odefsey
Brand Names: Canada
  • Odefsey
Pharmacologic Category
  • Antiretroviral, Reverse Transcriptase Inhibitor, Non-nucleoside (Anti-HIV);
  • Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV);
  • Antiretroviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HIV)
Dosing: Adult
HIV-1 infection, treatment

HIV-1 infection, treatment: Oral: One tablet (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg) once daily. Note: Do not use in patients with HIV RNA ≥100,000 copies/mL and/or CD4 count ≤200 cells/mm3 (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Note: Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.

CrCl ≥30 mL/minute: No dosage adjustment necessary.

CrCl <30 mL/minute: Use is not recommended.

End-stage renal disease on hemodialysis: No dosage adjustment necessary; administer after hemodialysis on dialysis days.

Dosing: Liver Impairment: Adult

Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustments necessary.

Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Rilpivirine, emtricitabine, and tenofovir alafenamide: Pediatric drug information")

Note: Product is a fixed-dose combination; use not recommended in other weight groups.

HIV-1 infection, treatment

HIV-1 infection, treatment: Note: Do not start in patients with HIV RNA ≥100,000 copies/mL (Ref). Evaluate gene mutation and antiretroviral resistance patterns (refer to https://www.iasusa.org and https://hivdb.stanford.edu/ for more information).

Children and Adolescents weighing ≥25 kg: Oral: Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg per tablet): One tablet once daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Children and Adolescents weighing ≥25 kg:

Baseline impairment:

CrCl ≥30 mL/minute: No dosage adjustment necessary.

CrCl <30 mL/minute at initiation of therapy: Use is not recommended.

End-stage renal disease on hemodialysis: Adolescents: No dosage adjustment necessary; administer after hemodialysis on dialysis days (Ref).

Nephrotoxicity during therapy (patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome): Discontinue therapy.

Dosing: Liver Impairment: Pediatric

Children and Adolescents weighing ≥25 kg:

Mild to moderate impairment: No dosage adjustment necessary.

Severe impairment: There are no dosage recommendations in the manufacturer's labeling (has not been studied).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.

1% to 10%:

Gastrointestinal: Diarrhea (1%), flatulence (≤1%), nausea (1%)

Nervous system: Abnormal dreams (1%), headache (2%), sleep disturbance (2%)

Neuromuscular & skeletal: Decreased bone mineral density (1% to 2%)

Frequency not defined: Endocrine & metabolic: Dyslipidemia

Contraindications

Concurrent use with certain drugs whose coadministration may result in loss of virologic response and possible resistance to emtricitabine/rilpivirine/tenofovir alafenamide or to the class of non-nucleoside reverse transcriptase inhibitors (eg, carbamazepine, systemic dexamethasone [>1 dose], oxcarbazepine, phenobarbital, phenytoin, proton pump inhibitors [dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole], rifampin, rifapentine, St John's wort).

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to emtricitabine, rilpivirine, tenofovir alafenamide, or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Depressive disorders: Rilpivirine may cause depression, depressed mood, dysphoria, major depression, mood changes, negative thoughts, suicide attempts, or suicidal ideation. Promptly evaluate patients with severe depressive symptoms and reevaluate risk versus benefit of continued combination therapy.

• Hepatotoxicity: Hepatotoxicity has been reported with rilpivirine-containing regimens. Patients with hepatitis B or C or increased baseline liver function tests may be at greater risk, although some cases have occurred in patients with no preexisting disease or hepatic disease risk factors. Evaluate liver function tests in patients with increased baseline liver function tests or with hepatitis B or C prior to treatment initiation and periodically during therapy; also consider evaluation of patients with no preexisting hepatic disease or hepatic disease risk factors.

• Hypersensitivity: Hypersensitivity and severe skin reactions have been reported, including drug reaction with eosinophilia and systemic symptoms (DRESS), with regimens containing rilpivirine. Some skin reactions were accompanied by constitutional symptoms (eg, fever); other skin reactions were associated with organ dysfunction (eg, hepatic serum biochemistry elevations). In clinical trials, treatment-related rashes ≥ grade 2 were reported in 1% of patients. Most rashes were grade 1 or 2 and occurred within the first 4 to 6 weeks of therapy. Monitor laboratory parameters and clinical status; discontinue if any severe hypersensitivity or skin rash (including, but not limited to, severe rash or rash accompanied by angioedema, blisters, conjunctivitis, eosinophilia, facial edema, fever, hepatitis, or mucosal involvement) develops.

• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome, autoimmune hepatitis) later in therapy; further evaluation and treatment may be required.

• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with the use of nucleoside analogs, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (marked transaminase elevation may/may not accompany hepatomegaly and steatosis).

• QT prolongation: In healthy subjects, supratherapeutic dosages of rilpivirine (75 mg once daily and 300 mg once daily) have been shown to prolong the QTc interval of the electrocardiogram; consider alternative therapy in patients at high risk for torsades de pointes or when coadministered with medications with known risk for torsades de pointes.

• Renal toxicity: Renal toxicity (acute renal failure, Fanconi syndrome, and/or proximal renal tubulopathy) has been reported with use of tenofovir alafenamide-containing products; most cases were characterized by potential confounders that may have contributed to the renal events; however, it is also possible these factors may have predisposed patients to tenofovir-related adverse events. Patients with impaired renal function and those with concurrent or recent nephrotoxic therapy (including NSAID use) are at an increased risk. Discontinue use in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.

Disease-related concerns:

• Renal impairment: Use is not recommended in patients with CrCl <30 mL/minute (unless receiving hemodialysis).

Warnings: Additional Pediatric Considerations

Emtricitabine-associated hyperpigmentation occurs more frequently in pediatric patients (32%) than in adults.

Incidence of some adverse reactions may be higher in pediatric patients 12 to 18 years of age receiving rilpivirine as compared to adults. In a small, phase 2 pediatric clinical trial (n=36), adverse reactions following receipt of rilpivirine in combination with other antiretrovirals were similar to those in adults, with a higher incidence of some reactions (eg, headache, dizziness, depression); most were grade 1 or 2. For depressive disorders, the incidence of grade 3 and 4 depressive disorders (regardless of causality) was 5.6% (vs 1% in adults), including 1 suicide attempt. None of these pediatric patients discontinued therapy due to their depressive symptoms.

Through disruption in vitamin D metabolism, decreases in bone mineral density (BMD) have been observed with tenofovir alafenamide (TAF) after 48 weeks of treatment; however, the incidence and negative impact on BMD is less than that observed with tenofovir disoproxil fumarate (TDF). Additionally, TAF is associated with less renal toxicity than TDF but equal antiviral efficacy. A higher incidence of dyslipidemia has been reported with TAF than TDF. TAF is preferred over TDF whenever possible; do not use TAF and TDF concomitantly (HHS [pediatric] 2024).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Odefsey: Emtricitabine 200 mg, rilpivirine 25 mg, and tenofovir alafenamide 25 mg

Generic Equivalent Available: US

No

Pricing: US

Tablets (Odefsey Oral)

200-25-25 mg (per each): $153.48

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Odefsey: Emtricitabine 200 mg, rilpivirine 25 mg, and tenofovir alafenamide 25 mg

Administration: Adult

Oral: Administer with a meal (≥390 kcal) (Ref).

Administration: Pediatric

Oral: Administer with a moderate to high-fat meal (children: ≥500 kcal; adolescents: ≥390 kcal); a protein drink alone is not sufficient (Ref).

Use: Labeled Indications

HIV-1 infection, treatment: Treatment of HIV-1 infection (as a complete regimen) in adult and pediatric patients weighing ≥25 kg as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA ≤100,000 copies/mL; or to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components.

Limitations of use: More rilpivirine-treated patients with no history of antiretroviral treatment with HIV-1 RNA >100,000 copies/mL at therapy initiation experienced virologic failure (HIV-1 RNA ≥50 copies/mL) compared to rilpivirine-treated patients with HIV-1 RNA ≤100,000 copies/mL.

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acyclovir-Valacyclovir: May increase serum concentration of Tenofovir Products. Tenofovir Products may increase serum concentration of Acyclovir-Valacyclovir. Risk C: Monitor

Adefovir: May decrease therapeutic effects of Tenofovir Products. Adefovir may increase serum concentration of Tenofovir Products. Tenofovir Products may increase serum concentration of Adefovir. Risk X: Avoid

Aminoglycosides: May increase serum concentration of Tenofovir Products. Tenofovir Products may increase serum concentration of Aminoglycosides. Risk C: Monitor

Antacids: May decrease serum concentration of Rilpivirine. Management: Administer antacids at least 2 hours before or 4 hours after oral rilpivirine when used with most rilpivirine products. However, administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product. Risk D: Consider Therapy Modification

Antihepaciviral Combination Products: May increase serum concentration of Rilpivirine. Risk X: Avoid

Atidarsagene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Atidarsagene Autotemcel. Risk X: Avoid

Betibeglogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Betibeglogene Autotemcel. Risk X: Avoid

Cabozantinib: MRP2 Inhibitors may increase serum concentration of Cabozantinib. Risk C: Monitor

CarBAMazepine: May decrease serum concentration of Rilpivirine. Risk X: Avoid

CarBAMazepine: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Cidofovir: May increase serum concentration of Tenofovir Products. Tenofovir Products may increase serum concentration of Cidofovir. Risk C: Monitor

Cladribine: Agents that Undergo Intracellular Phosphorylation may decrease therapeutic effects of Cladribine. Risk X: Avoid

Cobicistat: May increase serum concentration of Tenofovir Alafenamide. Risk C: Monitor

CYP3A4 Inducers (Moderate): May decrease serum concentration of Rilpivirine. Risk C: Monitor

CYP3A4 Inducers (Strong): May decrease serum concentration of Rilpivirine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for reduced rilpivirine efficacy (eg, loss of virologic response or resistance). Risk X: Avoid

CYP3A4 Inhibitors (Strong): May increase serum concentration of Rilpivirine. Risk C: Monitor

DexAMETHasone (Systemic): May decrease serum concentration of Rilpivirine. Risk X: Avoid

Didanosine: Rilpivirine may decrease absorption of Didanosine. Didanosine may decrease absorption of Rilpivirine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food. Management: Administer didanosine on an empty stomach at least 2 hours before or 4 hours after rilpivirine, due to the requirement that rilpivirine be administered with food. Risk D: Consider Therapy Modification

Elivaldogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Elivaldogene Autotemcel. Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished Risk X: Avoid

Ergonovine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase serum concentration of Ergonovine. Specifically, this would be most likely with delavrdine, while other Non-Nucleoside Reverse Transcriptase Inhibitors may be more likely to decrease the concentration of Ergonovine. Risk X: Avoid

Fosphenytoin: May decrease serum concentration of Rilpivirine. Risk X: Avoid

Ganciclovir-Valganciclovir: Tenofovir Products may increase serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase serum concentration of Tenofovir Products. Risk C: Monitor

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may increase QTc-prolonging effects of Haloperidol. Risk C: Monitor

Histamine H2 Receptor Antagonists: May decrease serum concentration of Rilpivirine. Management: Administer histamine H2 receptor antagonists (H2RAs) at least 12 hours before or 4 hours after oral rilpivirine. Risk D: Consider Therapy Modification

Inhibitors of the Proton Pump (PPIs and PCABs): May decrease serum concentration of Rilpivirine. Risk X: Avoid

Ketoconazole (Systemic): May increase serum concentration of Rilpivirine. Rilpivirine may decrease serum concentration of Ketoconazole (Systemic). Risk C: Monitor

Levomethadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease serum concentration of Levomethadone. Management: Levomethadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well. Risk C: Monitor

Lovotibeglogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Lovotibeglogene Autotemcel. Risk X: Avoid

Macrolide Antibiotics: May increase serum concentration of Rilpivirine. Management: Consider the use of azithromycin or another non-macrolide alternative when appropriate to avoid this potential interaction. Risk D: Consider Therapy Modification

Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase metabolism of Methadone. Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well. Risk C: Monitor

Nirmatrelvir and Ritonavir: May increase serum concentration of Tenofovir Alafenamide. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents (Topical): May increase nephrotoxic effects of Tenofovir Products. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents: May increase nephrotoxic effects of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk. Risk D: Consider Therapy Modification

Orlistat: May decrease serum concentration of Antiretroviral Agents. Risk C: Monitor

OXcarbazepine: May decrease serum concentration of Rilpivirine. Risk X: Avoid

OXcarbazepine: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

P-glycoprotein/ABCB1 Inducers: May decrease serum concentration of Tenofovir Alafenamide. Management: Consider alternatives to the use of P-gp inducers with tenofovir alafenamide. If combined, monitor for reduced tenofovir alafenamide concentrations and efficacy, and for the development of resistance. Risk D: Consider Therapy Modification

PHENobarbital: May decrease serum concentration of Rilpivirine. Risk X: Avoid

PHENobarbital: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Phenytoin: May decrease serum concentration of Rilpivirine. Risk X: Avoid

Primidone: May decrease serum concentration of Rilpivirine. Risk X: Avoid

Primidone: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may increase QTc-prolonging effects of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase adverse/toxic effects of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, efavirenz and nevirapine may decrease the serum concentrations of other non-nucleoside reverse transcriptase inhibitors. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, delavirdine may increase the serum concentration of etravirine. Risk X: Avoid

Rifabutin: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

RifAMPin: May decrease serum concentration of Rilpivirine. Risk X: Avoid

RifAMPin: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Rifapentine: May decrease serum concentration of Rilpivirine. Risk X: Avoid

Rifapentine: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Ritonavir: May increase serum concentration of Tenofovir Alafenamide. Risk C: Monitor

Saquinavir: Rilpivirine may increase arrhythmogenic effects of Saquinavir. Saquinavir may increase serum concentration of Rilpivirine. Risk X: Avoid

St John's Wort: May decrease serum concentration of Rilpivirine. Risk X: Avoid

St John's Wort: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Tacrolimus (Systemic): Tenofovir Products may increase nephrotoxic effects of Tacrolimus (Systemic). Risk C: Monitor

Tipranavir: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Reproductive Considerations

This fixed-dose combination of emtricitabine, rilpivirine, and tenofovir alafenamide is an alternative regimen for patients with HIV who are not yet pregnant but are trying to conceive (HHS [perinatal] 2024).

Refer to individual monographs for additional information.

Pregnancy Considerations

This fixed-dose combination of emtricitabine, rilpivirine, and tenofovir alafenamide is an alternative regimen for initiation in pregnant patients with HIV who are antiretroviral naive, who have had antiretroviral therapy (ART) in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). Patients who become pregnant while taking this combination may continue if viral suppression is effective and the regimen is well tolerated. More frequent monitoring (every 1 to 2 months) is recommended during pregnancy. This fixed-dose combination may be considered for patients when significant drug interactions would occur with preferred agents or in patients who need the convenience of a co-formulated single dose tablet in a once-daily regimen but are not eligible for preferred agents. This combination should only be used in pregnant patients with a pretreatment HIV RNA ≤100,000 copies/mL or CD4 cell count ≥200 cells/mm3 (HHS [perinatal] 2024).

Refer to individual monographs for additional information.

Breastfeeding Considerations

Emtricitabine, rilpivirine, and tenofovir are present in breast milk.

Refer to individual monographs for additional information.

Dietary Considerations

Take with a meal.

Monitoring Parameters

CD4 count, HIV RNA plasma levels; serum creatinine, estimated creatinine clearance, urine glucose, urine protein (prior to initiation and as clinically indicated during therapy); serum phosphorus (patients with chronic kidney disease); hepatic function tests, bone density (patients with a history of bone fracture or have risk factors for bone loss); fever, skin reactions, and/or hypersensitivity reactions; HBV testing (prior to or when initiating therapy). Patients with HIV and HBV coinfection should be monitored for several months following therapy discontinuation.

Mechanism of Action

Non-nucleoside, nucleoside, and nucleotide reverse transcriptase inhibitor combination; rilpivirine binds to reverse transcriptase and does not require intracellular phosphorylation for antiviral activity; emtricitabine is a cytidine analogue while tenofovir alafenamide fumarate (TAF) is an analog of adenosine 5'-monophosphate. Each drug interferes with HIV viral RNA dependent DNA polymerase activities resulting in inhibition of viral replication.

Pharmacokinetics (Adult Data Unless Noted)

See individual agents.

  1. Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel. JAMA. 2023;329(1):63-84. doi:10.1001/jama.2022.22246 [PubMed 36454551]
  2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2025.
  3. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; September 2021.
  4. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide fumarate) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada, Inc; November 2019.
  5. US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Updated January 20, 2022. Accessed May 9, 2022.
  6. US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new. Updated March 23, 2023. Accessed May 16, 2023.
  7. US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new. Updated September 12, 2024. Accessed February 25, 2025.
  8. US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfo.nih.gov. Updated April 27, 2021. Accessed May 14, 2021.
  9. US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new. Updated December 19, 2024. Accessed February 25, 2025.
  10. US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. https://clinicalinfo.hiv.gov/en/guidelines/perinatal. Updated December 19, 2024. Accessed December 30, 2024.
Topic 107096 Version 167.0